Lupin Q1 FY27 Results: Revenue Rs 7,171 Cr, PAT Rs 2,714 Cr and Key Highlights
- August 7, 2026
- Posted by: Kunal Singla
- Category: News
Lupin Q1 FY27 results declared Aug 6, 2026. Revenue Rs 7,171 Cr (+25.63% YoY). PAT Rs 2,714 Cr (+27.56% YoY). CMP Rs 2385.0 (-0.13%).
Lupin Q1 FY27 results were announced on August 6, 2026, on a Standalone basis. Lupin Q1 FY27 results show revenue grew +25.63% year-on-year to Rs 7,171 Cr from Rs 5,708 Cr in Q1 FY26, reflecting sustained demand in the Pharmaceuticals segment. The broader Nifty Pharma index also reflected mixed sentiment during the quarter.
Operating profit improved +38.79% YoY to Rs 3,543 Cr from Rs 2,552 Cr, indicating stronger operational efficiency. PAT rose +27.56% YoY to Rs 2,714.00 Cr from Rs 2,128.00 Cr in Q1 FY26. The quarterly numbers offer a detailed picture of how the company is navigating the current pharmaceuticals environment.
Click Here – Get Free Investment Predictions
Lupin Q1 FY27 Financial Highlights
| Metric | Q1 FY27 (Rs Cr) | Q1 FY26 (Rs Cr) | YoY Change |
|---|---|---|---|
| Lupin Revenue | 7,171 | 5,708 | +25.63% |
| Operating Profit | 3,543 | 2,552 | +38.79% |
| Net Profit (PAT) | 2,714 | 2,128 | +27.56% |
| Reporting Basis | Standalone | ||
Lupin Q1 FY27 Performance Analysis
Check the Univest Screener for Live Data on This Stock
Lupin Q1 FY27 results reflect healthy fundamentals across key financial parameters. Revenue momentum continued on a strong footing with the top line reaching Rs 7,171 Cr for the April to June 2026 quarter.
Operating profit stood at Rs 3,543 Cr, expanding +38.79% YoY. Margin improvement signals better cost absorption and product mix optimisation.
PAT of Rs 2,714 Cr marks a +27.56% year-on-year improvement. Investors monitoring Lupin Q1 FY27 results will note this as a key milestone for FY27 tracking.
Key Business Factors in Lupin Q1 FY27 Results
Revenue Growth Momentum in the Pharmaceuticals Segment
Lupin Q1 FY27 results demonstrate consistent top-line expansion, with revenue rising +25.63% YoY to Rs 7,171 Cr. Volume-led growth and pricing discipline in key markets drove the uptick.
Operating Margin Expansion Signals Efficiency Gains
Operating profit in Lupin Q1 FY27 results rose +38.79% YoY to Rs 3,543 Cr. This reflects tighter cost control, better product mix, and operating leverage as the company scales volumes in core business lines.
PAT Performance and Profitability Trend
Net profit in Lupin Q1 FY27 results stood at Rs 2,714 Cr (+27.56% YoY). The sustained PAT growth reflects the company’s improving financial profile.
Dividend Details
No dividend was announced along with Lupin Q1 FY27 results. The company is likely retaining earnings for reinvestment into growth capex and working capital requirements.
FY27 Outlook for Lupin
Lupin is positioned to maintain growth momentum into Q2 FY27 and beyond, supported by order visibility, operational improvements, and sector tailwinds. Management guidance points toward continued expansion in the Pharmaceuticals business with a focus on margin improvement and market share consolidation. Investors tracking Lupin Q1 FY27 results are advised to consult a SEBI-registered financial advisor before making decisions.
Lupin Stock Performance After Q1 FY27 Results
Download the Univest iOS App or Univest Android App to track Lupin live price and get daily stock recommendations.
Lupin shares were trading lower at Rs 2385.0 (-0.13%) on August 6, 2026, following the declaration of Lupin Q1 FY27 results. The stock reaction reflects investor sentiment on near-term earnings trajectory and sector outlook. CMP stood at Rs 2385.0 on the results date, with a 52-week range reflecting the broader market sentiment toward the pharmaceuticals sector.
Key Risks for Lupin
Sector-Specific Headwinds
US FDA regulatory actions, pricing pressure in generics, and USFDA import alerts remain core risks.
Valuation and Earnings Risk
Valuation risk remains if earnings growth fails to sustain at current levels over the next two to three quarters.
Operational and Financial Risk
Working capital intensity and cash conversion cycle elongation pose risks to standalone cash flows.
Conclusion
Lupin Q1 FY27 results demonstrate healthy financial performance with revenue at Rs 7,171 Cr and PAT at Rs 2,714 Cr on a Standalone basis. Operating leverage and disciplined cost management will be key drivers for the rest of FY27. Investors should track upcoming management commentary on growth drivers and sector developments before taking positions.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Lupin Q1 FY27 Results
When were Lupin Q1 FY27 results declared?
Ans. Lupin Q1 FY27 results were declared on August 6, 2026. The results cover the April to June 2026 quarter on a Standalone basis.
What was Lupin revenue in Q1 FY27?
Ans. Lupin Q1 FY27 results show revenue of Rs 7,171 Cr, +25.63% compared to Rs 5,708 Cr in Q1 FY26.
What was Lupin PAT in Q1 FY27?
Ans. Net profit (PAT) in Lupin Q1 FY27 results was Rs 2,714 Cr, +27.56% year-on-year.
Did Lupin declare a dividend in Q1 FY27?
Ans. No dividend was declared alongside Lupin Q1 FY27 results. Investors should check the official company announcements on BSE and NSE for any future dividend declarations.
What is the FY27 outlook for Lupin?
Ans. Lupin management has outlined a focus on revenue scaling and margin improvement for the remainder of FY27. Sector tailwinds and order book visibility will be key monitorables.
How did the Lupin stock react to Q1 FY27 results?
Ans. Lupin shares were trading lower at Rs 2385.0 (-0.13%) on August 6, 2026, following the Lupin Q1 FY27 results announcement. Investors should consult a SEBI-registered financial advisor before acting on price movements.
